Find Almitrine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Almitrine dimesylate, 29608-49-9, Almitrine bismesylate, Almitrine dimethanesulfonate, Almitrine dimesilate, Vectarion
Molecular Formula
C28H37F2N7O6S2
Molecular Weight
669.8  g/mol
InChI Key
MRDBGMJEPGXQHJ-UHFFFAOYSA-N
FDA UNII
6RY6V6XM8T

Almitrine
A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.
1 2D Structure

Almitrine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine;methanesulfonic acid
2.1.2 InChI
InChI=1S/C26H29F2N7.2CH4O3S/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20;2*1-5(2,3)4/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33);2*1H3,(H,2,3,4)
2.1.3 InChI Key
MRDBGMJEPGXQHJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
2.2 Other Identifiers
2.2.1 UNII
6RY6V6XM8T
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Almitrine

2. Almitrine Bis(methanesulfonate)

3. Almitrine Bismesylate

4. Almitrine Dimesylate

5. Almitrine Monomesylate

6. Monomesylate, Almitrine

7. Vectarion

2.3.2 Depositor-Supplied Synonyms

1. Almitrine Dimesylate

2. 29608-49-9

3. Almitrine Bismesylate

4. Almitrine Dimethanesulfonate

5. Almitrine Dimesilate

6. Vectarion

7. Almitrine Mesilate

8. Almitrine Mesylate [usan]

9. Almitrine Bismesilate

10. 6ry6v6xm8t

11. 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-n,4-n-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine;methanesulfonic Acid

12. Chebi:53779

13. S-2620

14. N2,n4-diallyl-6-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1,3,5-triazine-2,4-diamine Dimethanesulfonate

15. Almitrine Mesylate (usan)

16. (diallylamino-4'-6'-triazinyl-2')-1-(bis P-fluorobenzydryl)-4 Piperazine Bis Methanesulfonate

17. 2,4-bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine Dimethanesulfonate

18. 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine Dimethanesulfonate

19. Unii-6ry6v6xm8t

20. S 2620 Bismethanesulfonate

21. Almitrine Bismethane Sulfonate

22. Almitrinemesylate

23. Vectarion (tn)

24. Einecs 249-726-1

25. Almitrine Bismethanesulfonate

26. Dsstox_cid_31492

27. Dsstox_rid_97377

28. Dsstox_gsid_57703

29. Schembl2228917

30. Chembl3181957

31. Dtxsid5057703

32. Tox21_113959

33. Almitrine Dimesilate [mart.]

34. Mfcd01679060

35. S4439

36. Almitrine Dimesilate [who-dd]

37. Akos027327548

38. Almitrine Dimethanesulfonate [mi]

39. Ncgc00262968-01

40. Ds-11817

41. Cas-29608-49-9

42. Hy-107319

43. Cs-0028130

44. D02822

45. 608a499

46. Q27104813

47. 1,3,5-triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-, Dimethanesulfonate

48. 2,4-bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine Dimethanesulphonate

49. 6-4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine Dimethanesulfonate

50. 6-4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine Dimethanesulphonate

51. N,n'-diallyl-6-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1,3,5-triazine-2,4-diamine Dimethanesulphonate

52. N,n'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine Dimethanesulfonate

53. N2,n4-diallyl-6-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1,3,5-triazine-2,4-diaminedimethanesulfonate

2.4 Create Date
2006-07-28
3 Chemical and Physical Properties
Molecular Weight 669.8 g/mol
Molecular Formula C28H37F2N7O6S2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count15
Rotatable Bond Count10
Exact Mass669.22148060 g/mol
Monoisotopic Mass669.22148060 g/mol
Topological Polar Surface Area195 Ų
Heavy Atom Count45
Formal Charge0
Complexity694
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Respiratory System Agents

Drugs used for their effects on the respiratory system. (See all compounds classified as Respiratory System Agents.)


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty